Tech Company Financing Transactions
Regenacy Pharmaceuticals Funding Round
On 3/26/2020, Regenacy Pharmaceuticals raised $30 million in Series A funding from Cobro Ventures, Taiwania Capital and 3E Bioventures.
Transaction Overview
Company Name
Announced On
3/26/2020
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series A
Investors
Cobro Ventures (Lead Investor) (Marc Cohen)
Taiwania Capital (Lead Investor) (Michael Huang)
Proceeds Purpose
Regenacy plans to use the proceeds to initiate a Phase 2 proof-of-concept trial for ricolinostat, an oral, selective histone deacetylase 6 (HDAC6) inhibitor, in diabetic peripheral neuropathy (DPN).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
303 Wyman St. 300
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Overview
Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Simon Jones
Chief Financial Officer
John Rocha
Chief Medical Officer
David Michelson
VP - R & D
Matthew Jarpe
VP - Regulatory Affairs
Timothy Kachmar
Browse more venture capital transactions:
Prev: 3/26/2020: SecondNature venture capital transaction
Next: 3/26/2020: Espressive venture capital transaction
Share this article
About Database of VC Transactions
We report on all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs